Applications published 22 July 2009

Amine base salts of SAHA and polymorphs thereof
Merck & Co 2079304*

• Synthetic agonists of TLR9
Idera Pharmaceuticals 2079305*

• Mucosally non-irritative amphotericin B formulations and methods for treating non-invasive fungus-induced mucositis
Accentia Biopharmaceuticals 2079306*

• Farnesoid X receptor agonists
Smithkline Beecham 2079307*

• SMAC mimetic dimers and trimers useful as anti-cancer agent
Joyant Pharmaceuticals 2079309*

• Topical antibiotic compsn for the prevention of lyme disease
Ixodes 2079441*

• Use of glycerophospholipids for joint lubrication
Hadasit Medical Research 2079442*

• Dual action, inhaled formulations providing both an immediate and sustained release profile
Aradigm 2079443*

• Particles for cell targeting
Board of Regents, The University of Texas System; The Ohio State University Research Foundation 2079444*

• Stable digestive enzyme compsns
Eurand Pharmaceuticals 2079445*

• Paliperidone sustained release formulation
Teva Pharmaceutical Industries 2079446*

• Pharmaceutical solid dosage forms comprising compounds micro-embedded in ionic water-insoluble polymers
F Hoffmann-La Roche 2079447*

• Improved release of statins in the intestine
Dexcel Pharma Technologies 2079448*

• Phenylalkylamino carbamate compsns
Janssen Pharmaceutica 2079449*

• Method of preparing solid dosage forms of multi-phasic pharmaceutical compsns
Novavax 2079450*

• Combined preparation for the treatment of cardiovascular diseases based on chronotherapy
Hanall Pharmaceutical 2079451*

• Controlled release pharmaceutical compsn containing thiazides and angiotensin-II-receptor blockers
Hanall Pharmaceutical 2079452*

• Robust sustained release formulations
Penwest Pharmaceuticals 2079453*

• Sugar coatings and methods therefor
Wyeth 2079454*

• Pharmaceutical compsn comprising a dihydrobenzofuranyl isoindoline and a lipophilic component
Takeda Pharmaceutical 2079455*

• Pharmaceutical cyclosporin compsns
Sigmoid Pharma 2079456*

• A method of administering a film product containing a drug
Monosol RX 2079457*

• Transdermal therapeutic system with two-phase releasing profile
Axxonis Pharma 2079458*

• Method of treating asthma, allergic rhinitis, and skin disorders
Alcon Research 2079459*

• Cosmetic oral and/or parenteral use of glucosamine optionally in combination with at least one polyphenol compound, and corresponding compsns
Laboratories Inneov 2079460*

• Methods of hormonal treatment utilising ascending-dose extended cycle regimens
Duramed Pharmaceuticals 2079461*

• Pharmaceutical compsns of HDAC inhibitors and chelatable metal compounds, and metal-HDAC inhibitor chelate complexes
Merck & Co 2079462*

• Crystalline forms of aliskiren hemifumarate
Novartis 2079463*

• Intravenous and oral dosing of a direct-acting and reversible P2Y12 inhibitor
Portola Pharmaceuticals 2079464*

• Methods for treatment of cochlear and vestibular disorders
Janssen Pharmaceutica 2079465*

• Substituted indole compounds
SmithKline Beecham 2079466*

• Antidiabetic bicyclic compounds
Merck & Co 2079467*

• Oral care compsns containing combinations of anti-bacterial and host-response modulating agents
Procter & Gamble 2079468*

• Use of dipeptidyl peptidase IV inhibitors for preventing, delaying or reducing the occurrence of oedema
Novartis 2079469*

• Compsn comprising an NK-1 receptor antagonist and an SSRI for the treatment of tinnitus and hearing loss
Glaxo Group 2079470*

• Food extracts containing N-methylnicotinamide for treatment of lipoprotein abnormalities and skin diseases and disorders
Dermena 2079471*

• High-purity large-scale preparation of stannsoporfin
InfaCare Pharmaceutical 2079472*

• Dermatological compsns containing avermectin nanocapsules, method for preparing the same and uses thereof
Galderma 2079473*

• Liposome encapsulated poly-ICLC method to prophylactically treat an avian influenza viral infection
Her Majesty the Queen, in right of Canada, as represented by the Minister of National Defence 2079474*

• Uses of water-soluble cellulose derivatives for preventing or treating metabolic syndrome
Dow Global Technologies; United States Department of Agriculture 2079476*

• Materials and methods for treating and managing angiogenesis-mediated diseases
Pervasis Therapeutics 2079478*

• HCV NS3 protease inhibitors
Merck & Co; Istituto di Richerche di Biologia Molecolare 2079479*

• HCV NS3 protease inhibitors
Merck 2079480*

• Monitoring cancer stem cells
Stemline Therapeutics 2079484*

• Phenylpropionamide compounds and the use thereof
Purdue Pharma 2079485*

• Efficient synthesis of chelators for nuclear imaging and radiotherapy: compsns and applications
The Board of Regents of the University of Texas System 2079486*

• Dendritic chelated compounds, methods for making the same and pharmaceutical compsns containing the same
Centre National de la Recherche Scientifique; Universite Louis Pasteur 2079682*

• Di-fluoro containing compounds as cysteine protease inhibitors
ViroBay 2079683*

• Compsns containing, methods involving, and uses of non-natural amino acids and polypeptides
Ambrx 2079687*

• Glucagen receptor antagonist compounds, compsns containing such compounds and methods of use
Merck 2079688*

• Novel indole derivatives, process for the preparation thereof and pharmaceutical compsns containing them
Les Laboratoires Servier 2079689*

• 3-aza-bicyclo[3.1.0]hexane derivatives
Actelion Pharmaceuticals 2079690*

• Substituted indeno[1,2-B]indole derivatives as novel inhibitors of protein kinase CK2 and their use as tumour therapeutic agents, cytostatics and diagnostic aids
Heinrich-Heine-Universitaet Duesseldorf 2079691*

• Process for the preparation of 2,5-bis-(2,2,2-trifluoroethoxy)-N-(2-piperidylmethyl)-benzamide and salts thereof
Grindeks 2079692*

• Ether derivatives dual modulators of the 5-HT2A and D3 receptors
F Hoffmann-La Roche 2079693*

• N-substituted heterocycloalkyloxybenzamide compounds and methods of use
Rigel Pharmaceuticals 2079694*

• Phenylurea compounds as soluble epoxide hydrolase inhibitors
Arete Therapeutics 2079695*

• Kinase inhibitors
Takeda San Diego 2079696*

• Caspase inhibitors based on pyridazinone scaffold
LG LIfe Sciences 2079698*